• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
SHI Qinqing, WANG Jinghua, CHENG Manman, YIN Lifang, QIN Chao. Preparation and in vitro release of ivabradine hydrochloride elementary osmotic pump tablets[J]. Journal of China Pharmaceutical University, 2021, 52(3): 311-317. DOI: 10.11665/j.issn.1000-5048.20210307
Citation: SHI Qinqing, WANG Jinghua, CHENG Manman, YIN Lifang, QIN Chao. Preparation and in vitro release of ivabradine hydrochloride elementary osmotic pump tablets[J]. Journal of China Pharmaceutical University, 2021, 52(3): 311-317. DOI: 10.11665/j.issn.1000-5048.20210307
shu

Preparation and in vitro release of ivabradine hydrochloride elementary osmotic pump tablets

  • Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China(No.81871477)
More Information
  • Received Date: January 05, 2021
  • Revised Date: May 11, 2021
    Graphical Abstract
    • Abstract
  • In this study, ivabradine hydrochloride (IVB) was prepared as elementary osmotic pump tablets whose administration frequency was reduced to once daily. The dissolution method was developed, and effects on drug release profiles were evaluated by single factor analysis involving suspending agents, osmotic active agents and aging process. Orthogonal test was carried out at 3 levels on 3 factors including the amount of polyoxyethylene (PEO) in the core, polyethylene glycol (PEG) percentage and weight increase of controlled-release film coatings. The final formulation consisted of IVB (16.25 mg), PEO N80 (60 mg), hypromellose E5 (10 mg), lactose (111.75 mg), magnesium stearate (2 mg); and the film coatings consisted of PEG (15%), cellulose acetate (85%), with a weight increase of 7.5%. In vitro drug release behaviors were investigated. Prepared tablets exhibited similar release profiles in different pH dissolution media, with no risk of dose dumping in 40% ethanol solutions. The osmotic pressure differences inside and outside the membrane drove drug release. IVB osmotic pump tablets could reduce the frequency of administration and improve patients'' compliance, thus with better application values.
    • FullText(HTML)
    • References (15)
  • [1]
    . Pharmacol Res，2006，53（5）：424-434.
    [2]
    Li JD，Gan T. The clinical application of If current inhibitor ivabradine［J］. J Clin Cardiol（临床心血管病杂志），2020，36（3）：212-214.
    [3]
    Electronic Medicines CompendiumUK.Summary of product characteristics of procoralan［EB/OL］.（2019-01-25）［2021-01-06］.https：//www.medicines.org.uk/emc/product/166/smpc.
    [4]
    Mullasari A，investigatorsPROFICIENT. Efficacy and safety of ivabradine once-daily prolonged-release versus twice-daily immediate-release formulation in patients with stable chronic heart failure with systolic dysfunction：a randomized，double-blind，phase 3 non-inferiority （PROFICIENT） study［J］. Cardiol Ther，2020，9（2）：505-521.
    [5]
    Xu X，Wei YL，Ji W，et al. Pharmacokinetic profile of ivabradine hemisulfate sustained-release tablets administered in Chinese healthy volunteers：an open-label，randomized，single-dose，three-period crossover study［J］. Biomed Chromatogr，2019，33（11）：e4662.
    [6]
    Ma L. Progress in osmotic pump drug delivery system［J］. J China Pharm Univ（中国药科大学学报），2014，45（6）：726-730.
    [7]
    Thombre AG，Appel LE，Chidlaw MB，et al. Osmotic drug delivery using swellable-core technology［J］. J Control Release，2004，94（1）：75-89.
    [8]
    Malaterre V，Ogorka J，Loggia N，et al. Oral osmotically driven systems：30 years of development and clinical use［J］. Eur J Pharm Biopharm，2009，73（3）：311-323.
    [9]
    Zhu L，Qin C，Wu JL，et al. Preparation and in vitro evaluation of pregabalin controlled porosity osmotic pump tablets［J］. J China Pharm Univ（中国药科大学学报），2019，50（1）：53-58.
    [10]
    Masciocchi N，Aulisio A，Bertolini G，et al. Disclosing the extensive crystal chemistry of Ivabradine hydrochloride，in its pure and solvated phases［J］. Powder Diffr，2013，28（3）：200-206.
    [11]
    Zhou XB，Zhu JR，Liu JY，et al. Crystal structures and properties of two hydrated conglomerate forms of the heart-rate-lowering agent ivabradine hydrochloride［J］. Acta Crystallogr C Struct Chem，2019，75（Pt 5）：545-553.
    [12]
    Waterman KC，MacDonald BC，Roy MC. Extrudable core system：development of a single-layer osmotic controlled-release tablet［J］. J Control Release，2009，134（3）：201-206.
    [13]
    Smith AP，Moore TW，Westenberger BJ，et al. In vitro dissolution of oral modified-release tablets and capsules in ethanolic media［J］. Int J Pharm，2010，398（1/2）：93-96.
    [14]
    Jedinger N，Khinast J，Roblegg E. The design of controlled-release formulations resistant to alcohol-induced dose dumping：a review［J］. Eur J Pharm Biopharm，2014，87（2）：217-226.
    [15]
    Costa P，Sousa Lobo JM. Modeling and comparison of dissolution profiles［J］. Eur J Pharm Sci，2001，13（2）：123-133.
    • Related Articles

  • Related Articles

    [1]HOU Kai, LI Ping, ZHANG Jinlian, WANG Fang, YANG Yu. Blood coagulation factor XI: new strategy of targeted anticoagulant therapy[J]. Journal of China Pharmaceutical University, 2024, 55(5): 708-714. DOI: 10.11665/j.issn.1000-5048.2023050101
    [2]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [3]LIU Yanhong, CHEN Liqing, ZHANG Xintong, GAO Zhonghao, HUANG Wei. Research progress of tumor immunomodulation strategies based on nanodrug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 5-14. DOI: 10.11665/j.issn.1000-5048.2023021501
    [4]WANG Yanmei, YANG Lei, XIN Xiaofei, YIN Lifang. Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease[J]. Journal of China Pharmaceutical University, 2022, 53(4): 423-432. DOI: 10.11665/j.issn.1000-5048.20220405
    [5]ZHOU Xinyuan, LIU Nan, ZHANG Pan, HUO Meirong. Advances in research on therapeutic strategies of targeting pancreatic cancer stroma[J]. Journal of China Pharmaceutical University, 2021, 52(6): 653-662. DOI: 10.11665/j.issn.1000-5048.20210602
    [6]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [7]YANG Shan, XU Cheng, YAO Jing. Strategies of nano drug delivery system applied in anti-angiogenic therapy[J]. Journal of China Pharmaceutical University, 2019, 50(1): 11-18. DOI: 10.11665/j.issn.1000-5048.20190102
    [8]SONG Ke, PAN Hao, HAN Jiayi, CHEN Lijiang. Nano drug delivery system based strategies to target tumor microenvironment[J]. Journal of China Pharmaceutical University, 2018, 49(4): 392-400. DOI: 10.11665/j.issn.1000-5048.20180402
    [9]SU Zhigui, MO Ran, ZHANG Can. Advances of nano-drug delivery systems overcoming the physiological and pathological barriers of tumor[J]. Journal of China Pharmaceutical University, 2015, 46(1): 28-39. DOI: 10.11665/j.issn.1000-5048.20150103
    [10]KE Xue. Advances in targeted drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(1): 9-15.

  • Cited by

    Periodical cited type(2)

    1. 翟允耀，章晓骅. 化学仿制药制剂开发中晶型研究思路探讨. 药品评价. 2024(02): 131-133 .
    2. 梁霖霖，王志伟，何小双，衡伟利，钱帅，高缘，张建军，魏元锋. 机械外力对中药提取物晶体学固态形式及溶出速率的影响研究——以女贞子提取物为例. 中国药科大学学报. 2024(06): 767-774 . 本站查看

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365829

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return